2024-04-012025-03-312025-03-31false08661326LEAGRAVE CLINIC LIMITED2025-11-14falseiso4217:GBPxbrli:pure086613262024-03-31086613262025-03-31086613262024-04-012025-03-31086613262023-03-31086613262024-03-31086613262023-04-012024-03-3108661326bus:SmallEntities2024-04-012025-03-3108661326bus:AuditExempt-NoAccountantsReport2024-04-012025-03-3108661326bus:FullAccounts2024-04-012025-03-3108661326bus:PrivateLimitedCompanyLtd2024-04-012025-03-3108661326core:WithinOneYear2025-03-3108661326core:AfterOneYear2025-03-3108661326core:WithinOneYear2024-03-3108661326core:AfterOneYear2024-03-3108661326core:ShareCapital2025-03-3108661326core:SharePremium2025-03-3108661326core:RevaluationReserve2025-03-3108661326core:OtherReservesSubtotal2025-03-3108661326core:RetainedEarningsAccumulatedLosses2025-03-3108661326core:ShareCapital2024-03-3108661326core:SharePremium2024-03-3108661326core:RevaluationReserve2024-03-3108661326core:OtherReservesSubtotal2024-03-3108661326core:RetainedEarningsAccumulatedLosses2024-03-3108661326core:LandBuildings2025-03-3108661326core:PlantMachinery2025-03-3108661326core:Vehicles2025-03-3108661326core:FurnitureFittings2025-03-3108661326core:OfficeEquipment2025-03-3108661326core:NetGoodwill2025-03-3108661326core:IntangibleAssetsOtherThanGoodwill2025-03-3108661326core:ListedExchangeTraded2025-03-3108661326core:UnlistedNon-exchangeTraded2025-03-3108661326core:LandBuildings2024-03-3108661326core:PlantMachinery2024-03-3108661326core:Vehicles2024-03-3108661326core:FurnitureFittings2024-03-3108661326core:OfficeEquipment2024-03-3108661326core:NetGoodwill2024-03-3108661326core:IntangibleAssetsOtherThanGoodwill2024-03-3108661326core:ListedExchangeTraded2024-03-3108661326core:UnlistedNon-exchangeTraded2024-03-3108661326core:LandBuildings2024-04-012025-03-3108661326core:PlantMachinery2024-04-012025-03-3108661326core:Vehicles2024-04-012025-03-3108661326core:FurnitureFittings2024-04-012025-03-3108661326core:OfficeEquipment2024-04-012025-03-3108661326core:NetGoodwill2024-04-012025-03-3108661326core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3108661326core:ListedExchangeTraded2024-04-012025-03-3108661326core:UnlistedNon-exchangeTraded2024-04-012025-03-3108661326core:MoreThanFiveYears2024-04-012025-03-3108661326core:Non-currentFinancialInstruments2025-03-3108661326core:Non-currentFinancialInstruments2024-03-3108661326dpl:CostSales2024-04-012025-03-3108661326dpl:DistributionCosts2024-04-012025-03-3108661326core:LandBuildings2024-04-012025-03-3108661326core:PlantMachinery2024-04-012025-03-3108661326core:Vehicles2024-04-012025-03-3108661326core:FurnitureFittings2024-04-012025-03-3108661326core:OfficeEquipment2024-04-012025-03-3108661326dpl:AdministrativeExpenses2024-04-012025-03-3108661326core:NetGoodwill2024-04-012025-03-3108661326core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3108661326dpl:GroupUndertakings2024-04-012025-03-3108661326dpl:ParticipatingInterests2024-04-012025-03-3108661326dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-3108661326core:ListedExchangeTraded2024-04-012025-03-3108661326dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-3108661326core:UnlistedNon-exchangeTraded2024-04-012025-03-3108661326dpl:CostSales2023-04-012024-03-3108661326dpl:DistributionCosts2023-04-012024-03-3108661326core:LandBuildings2023-04-012024-03-3108661326core:PlantMachinery2023-04-012024-03-3108661326core:Vehicles2023-04-012024-03-3108661326core:FurnitureFittings2023-04-012024-03-3108661326core:OfficeEquipment2023-04-012024-03-3108661326dpl:AdministrativeExpenses2023-04-012024-03-3108661326core:NetGoodwill2023-04-012024-03-3108661326core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3108661326dpl:GroupUndertakings2023-04-012024-03-3108661326dpl:ParticipatingInterests2023-04-012024-03-3108661326dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3108661326core:ListedExchangeTraded2023-04-012024-03-3108661326dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3108661326core:UnlistedNon-exchangeTraded2023-04-012024-03-3108661326core:NetGoodwill2025-03-3108661326core:IntangibleAssetsOtherThanGoodwill2025-03-3108661326core:LandBuildings2025-03-3108661326core:PlantMachinery2025-03-3108661326core:Vehicles2025-03-3108661326core:FurnitureFittings2025-03-3108661326core:OfficeEquipment2025-03-3108661326core:AfterOneYear2025-03-3108661326core:WithinOneYear2025-03-3108661326core:ListedExchangeTraded2025-03-3108661326core:UnlistedNon-exchangeTraded2025-03-3108661326core:ShareCapital2025-03-3108661326core:SharePremium2025-03-3108661326core:RevaluationReserve2025-03-3108661326core:OtherReservesSubtotal2025-03-3108661326core:RetainedEarningsAccumulatedLosses2025-03-3108661326core:NetGoodwill2024-03-3108661326core:IntangibleAssetsOtherThanGoodwill2024-03-3108661326core:LandBuildings2024-03-3108661326core:PlantMachinery2024-03-3108661326core:Vehicles2024-03-3108661326core:FurnitureFittings2024-03-3108661326core:OfficeEquipment2024-03-3108661326core:AfterOneYear2024-03-3108661326core:WithinOneYear2024-03-3108661326core:ListedExchangeTraded2024-03-3108661326core:UnlistedNon-exchangeTraded2024-03-3108661326core:ShareCapital2024-03-3108661326core:SharePremium2024-03-3108661326core:RevaluationReserve2024-03-3108661326core:OtherReservesSubtotal2024-03-3108661326core:RetainedEarningsAccumulatedLosses2024-03-3108661326core:NetGoodwill2023-03-3108661326core:IntangibleAssetsOtherThanGoodwill2023-03-3108661326core:LandBuildings2023-03-3108661326core:PlantMachinery2023-03-3108661326core:Vehicles2023-03-3108661326core:FurnitureFittings2023-03-3108661326core:OfficeEquipment2023-03-3108661326core:AfterOneYear2023-03-3108661326core:WithinOneYear2023-03-3108661326core:ListedExchangeTraded2023-03-3108661326core:UnlistedNon-exchangeTraded2023-03-3108661326core:ShareCapital2023-03-3108661326core:SharePremium2023-03-3108661326core:RevaluationReserve2023-03-3108661326core:OtherReservesSubtotal2023-03-3108661326core:RetainedEarningsAccumulatedLosses2023-03-3108661326core:AfterOneYear2024-04-012025-03-3108661326core:WithinOneYear2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:CostValuation2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3108661326core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3108661326core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3108661326core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3108661326core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3108661326core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3108661326core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3108661326core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3108661326core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3108661326core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3108661326core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3108661326core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3108661326bus:Director12024-04-012025-03-3108661326bus:Director22024-04-012025-03-3108661326bus:Director32024-04-012025-03-3108661326core:FurnitureFittingsToolsEquipment2024-03-3108661326core:FurnitureFittingsToolsEquipment2024-04-012025-03-3108661326core:FurnitureFittingsToolsEquipment2025-03-31

LEAGRAVE CLINIC LIMITED

Registered Number
08661326
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2025

LEAGRAVE CLINIC LIMITED
Company Information
for the year from 1 April 2024 to 31 March 2025

Directors

HASSAN, Puja Sana
HASSAN, Riaz
HASSAN, Tanya

Registered Address

Fulford Lodge 1 Heslington Lane
Fulford
York
YO10 4HW

Registered Number

08661326 (England and Wales)
LEAGRAVE CLINIC LIMITED
Statement of Financial Position
31 March 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets332,05664,108
Tangible assets4148,043150,206
Investments515,03910,206
195,138224,520
Current assets
Stocks615,5005,208
Debtors7348,961332,630
Cash at bank and on hand51,510-
415,971337,838
Creditors amounts falling due within one year8(341,699)(291,588)
Net current assets (liabilities)74,27246,250
Total assets less current liabilities269,410270,770
Creditors amounts falling due after one year9(23,196)(26,510)
Provisions for liabilities11(36,264)(27,847)
Net assets209,950216,413
Capital and reserves
Called up share capital22
Profit and loss account209,948216,411
Shareholders' funds209,950216,413
The financial statements were approved and authorised for issue by the Board of Directors on 14 November 2025, and are signed on its behalf by:
HASSAN, Puja Sana
Director
HASSAN, Riaz
Director

Registered Company No. 08661326
LEAGRAVE CLINIC LIMITED
Notes to the Financial Statements
for the year ended 31 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
In March 2020 the UK was impacted by the outbreak of Covid-19. The Government imposed significant restrictions at that time in an effort to manage the spread of the virus which resulted in the company having to review and change its working practices to ensure compliance with these restrictions. More latterly, the UK economy has been impacted by rising inflation, interest rates and energy costs, exacerbated by the war in Ukraine. All these matters have impacted the company's trading results to a greater or lesser extent. At the date of signing these financial statements, the directors have considered the effect of these matters on the company with the information available to it and do not believe that it will affect the ability of the company to continue to trade for the foreseeable future. On this basis, the directors have prepared these financial statements on a going concern basis.
Turnover policy
The revenue shown in the profit and loss account represents income receivable from dental treatments carried out during the period. Revenue in respect of dental treatment uncompleted at the year end date is recognised by reference to the stage of completion.
Revenue from sale of goods
The revenue shown in the profit and loss account represents income receivable from dental treatments carried out during the period. Revenue in respect of dental treatment uncompleted at the year end date is recognised by reference to the state of completion.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight-line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery20
Fixtures and fittings20
Office Equipment20
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
Stocks and work in progress
Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

20252024
Average number of employees during the year2521
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 April 24320,533320,533
At 31 March 25320,533320,533
Amortisation and impairment
At 01 April 24256,425256,425
Charge for year32,05232,052
At 31 March 25288,477288,477
Net book value
At 31 March 2532,05632,056
At 31 March 2464,10864,108
4.Tangible fixed assets

Plant & machinery

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 April 24394,47262,49350,713507,678
Additions26,7945277,52834,849
At 31 March 25421,26663,02058,241542,527
Depreciation and impairment
At 01 April 24285,82940,05731,586357,472
Charge for year27,0884,5935,33137,012
At 31 March 25312,91744,65036,917394,484
Net book value
At 31 March 25108,34918,37021,324148,043
At 31 March 24108,64322,43619,127150,206
5.Fixed asset investments

Other investments1

Total

££
Cost or valuation
At 01 April 2410,20610,206
Additions4,8334,833
At 31 March 2515,03915,039
Net book value
At 31 March 2515,03915,039
At 31 March 2410,20610,206

Notes

1Other investments other than loans
6.Stocks

2025

2024

££
Raw materials and consumables15,5005,208
Total15,5005,208
7.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables104,349118,485
Amounts owed by group undertakings206,209178,533
Other debtors38,40334,233
Prepayments and accrued income-1,379
Total348,961332,630
8.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables48,1253,255
Bank borrowings and overdrafts21,02213,586
Amounts owed to related parties111,325127,988
Taxation and social security125,156131,328
Finance lease and HP contracts16,5009,192
Other creditors9,4366,239
Accrued liabilities and deferred income10,135-
Total341,699291,588
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
9.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts2,02512,475
Other creditors21,17114,035
Total23,19626,510
10.Obligations under finance leases

2025

2024

££
Finance lease and HP contracts37,67223,227
11.Provisions for liabilities

2025

2024

££
Net deferred tax liability (asset)36,26427,847
Total36,26427,847
12.Related party transactions
The company has taken advantage of the exemptions provided in FRS 102 from reporting transactions between wholly owned members of the group.
13.Controlling party
The company was under the control of Prudent Clinic limited, the ultimate holding company registered in England and Wales.